Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Share-based Compensation data on file, last reported at $9.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $9.4 million, up 7.82% year-over-year; the trailing twelve-month figure through Feb 2026 was $38.6 million (up 10.96% YoY), and the FY2025 annual result was $38.0 million, up 11.9% from the prior year.
• Share-based Compensation climbed to $9.4 million in Q1 2026 per NRIX's latest filing, from $9.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $10.4 million in Q2 2025 and troughed at $2.8 million in Q2 2022.
• A 5-year average of $8.0 million and a median of $8.5 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 213.89% in 2023, then declined 7.77% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $8.3 million in 2022, then slipped by 3.29% to $8.0 million in 2023, then advanced by 6.03% to $8.5 million in 2024, then advanced by 6.79% to $9.1 million in 2025, then gained by 3.5% to $9.4 million in 2026.
• Business Quant data shows NRIX's Share-based Compensation at $9.4 million in Q1 2026, $9.1 million in Q4 2025, and $9.8 million in Q3 2025.